Share This Article:

Gender Differences in Serum Prolactin Levels in Drug Naïve First Episode Schizophrenia

Abstract Full-Text HTML XML Download Download as PDF (Size:252KB) PP. 165-169
DOI: 10.4236/ojpsych.2015.52018    3,064 Downloads   3,395 Views   Citations

ABSTRACT

Objective: To determine if there is a significant rise in serum prolactin (PRL) in acute psychosis related to disease process and weather there is a significant gender difference in the level of PRL and its correlation psychopathology. Procedure: Naturalistic study involved 60 consenting outpatients and inpatients in a tertiary psychiatric setting. Patient base was comprised of men (n = 30) and women (n = 30) with 83% in the age range of 21 - 40 years old. All subjects had confirmed first episode diagnosis set forth by the Diagnostic and Statistical Manual of Mental Disorders. Patients were drug free and drug na?ve. Standardization for control was done using 15 control PRL samples obtained from healthy individuals. Methodology involved assessment by radioimmunoassay, the Brief Psychiatric Rating Scale and the Positive and Negative Syndrome Scale at day 1, 3 weeks and again at 6 weeks. All patients were treated with atypical antipsychotic drugs. Results: Serum PRL was elevated on baseline in 75% of first episode psychosis schizophrenia, yet found to have a negative correlation to psychopathology at base week 3 and week 6 samples. Conclusions: Elevated serum PRL is not a potential indicator of acute schizophrenia. Levels are higher in females than in males, yet females respond better to treatment at a lower dose than males.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

Shrivastava, A. , Shah, N. , Sousa, A. and Sonavane, S. (2015) Gender Differences in Serum Prolactin Levels in Drug Naïve First Episode Schizophrenia. Open Journal of Psychiatry, 5, 165-169. doi: 10.4236/ojpsych.2015.52018.

References

[1] Srerri, O., Chik, C.L., Ur, E. and Ezzat, S. (2003) Diagnosis and Management of Hyperprolactemia. CMAJ, 169, 575-581.
[2] Ghadirian, A.M., Chouinard, G. and Annable, L. (1982) Sexual Dysfunction and Plasma Prolactin Levels in Neuroleptic-Treated Schizophrenic Outpatients. Journal of Nervous & Mental Disease, 170, 463-467. http://dx.doi.org/10.1097/00005053-198208000-00004
[3] Kinon, B.J., Gilmore, J.A., Liu, H. and Halbreich, U.M. (2003) Prevalence of Hyperprolactinemia in Schizophrenic Patients Treated with Conventional Antipsychotic Medications or Risperidone. Psychoneuroendocrinology, 28, 55-68. http://dx.doi.org/10.1016/S0306-4530(02)00127-0
[4] Wickipedia (2006) Antipsychotic Drugs. http://en.wikipedia.org/wiki/Atypical_antipsychotic
[5] American Psychiatric Association (2000) Diagnostic and Statistical Manual for the Classification of Psychiatric Disorders. American Psychiatric Publishing, New York.
[6] Overall, J.E. and Gorham, D.R. (1988) The Brief Psychiatric Rating Scale (BPRS): Recent Developments in Ascertainment and Scaling. Psychopharmacology Bulletin, 24, 97-99.
[7] Leucht, S., Kane, J.M., Kissling, W., Hamann, J., Etschel, E. and Engel, R.R. (2005) What Does the PANSS Mean? Schizophrenia Research, 79, 231-238. http://dx.doi.org/10.1016/j.schres.2005.04.008
[8] Robinson, D.G., Woerner, M.G., Delman, H.M. and Kane, J.M. (2005) Pharmacological Treatments for First-Episode Schizophrenia. Schizophrenia Bulletin, 31, 705-722.
http://dx.doi.org/10.1093/schbul/sbi032
[9] Lieberman, J.A., Phillips, M., Gu, H., Stroup, S., Zhang, P., Kong, L., et al. (2003) Atypical and Conventional Antipsychotic Drugs in Treatment-Na?ve First-Episode Schizophrenia: A 52-Week Randomized Trial of Clozapine vs Chlorpromazine. Neuropsychopharmacology, 28, 995-1003.
[10] Woerner, M.G., Robinson, D.G., Alvir, J.M.J., Sheitman, B.B., Lieberman, J.A. and Kane, J.M. (2003) Clozapine as a First Treatment for Schizophrenia. The American Journal of Psychiatry, 160, 1514-1516. http://dx.doi.org/10.1176/appi.ajp.160.8.1514
[11] Brown, W.A. and Laughren, T.P. (1981) Tolerance to the Prolactin-Elevating Effect of Neuroleptics. Psychiatry Research, 5, 317-322. http://dx.doi.org/10.1016/0165-1781(81)90078-0
[12] Srivastava, A., Tamhane, M. and Kathrani, C.M. (1998) Serum Prolactin and Atypical Neuroleptics in Schizophrenia. Silver Mind Hospital, Mumbai.
[13] Melkersson, K.I., Hulting, A.-L. and Rane, A.J. (2001) Dose Requirement and Prolactin Elevation of Antipsychotics in Male and Female Patients with Schizophrenia or Related Psychoses. British Journal of Clinical Pharmacology, 51, 317-324. http://dx.doi.org/10.1046/j.1365-2125.2001.01352.x
[14] Canuso, C.M., Goldstein, J.M. and Green, A.I. (1998) The Evaluation of Women with Schizophrenia. Psychopharmacology Bulletin, 34, 271-277.
[15] Segal, M., Avital, A., Rojas, M., Hausvater, N., Sandbank, S., Liba, D., et al. (2004) Serum Prolactin Levels in Unmedicated First-Episode and Recurrent Schizophrenia Patients: A Possible Marker for the Disease’s Subtypes. Psychiatry Research, 127, 227-235.
http://dx.doi.org/10.1016/j.psychres.2004.01.010
[16] Maas, D.L., Hunt, S., Mark, L. and Drobny, E.C. (1996) Reversable Thioridazine-Induced Magnetic Resonance Imaging-Documented Pituitary Enlargement Associated with Hyperprolactinemia. Endocrine Practice, 2, 85-89. http://dx.doi.org/10.4158/EP.2.2.85

  
comments powered by Disqus

Copyright © 2018 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.